IHS Chemical Week

Regions :: Western Europe :: Denmark

Denmark's Novo acquires Xellia Pharmaceuticals in $700-million deal

3:06 AM MDT | May 22, 2013 | Francinia Protti-Alvarez

Novo A/S (Hellerup, Denmark), parent of pharmaceutical firm Novo Nordisk (Bagsvaerd, Denmark), has acquired Xellia Pharmaceuticals (Oslo) from private equity firm 3i (London) for an enterprise value of $700 million, 3i and Novo have announced. The company 3i says it reaped a 2.3-times return on the original $395-million investment made in 2008. The closing of the transaction will be subject to relevant competition law approvals and is expected to take place during the third quarter of 2013. "Xellia strongly complements our portfolio of significant...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa